Financial Performance Overview

Standalone Financial Results (FY 2025-26 vs FY 2024-25)

Indoco Remedies reported mixed financial results for FY26 with revenue growth but continued losses. Standalone revenue grew 9.3% to ₹1,633.5 crore (₹1,715.71 crore total income) but the company reported a net loss of ₹5.66 crore, slightly improved from ₹8.73 crore loss in FY25. Operating profit declined to ₹41.3 crore from ₹49.2 crore, while finance costs increased significantly to ₹88.5 crore (5.4% of sales).

Consolidated Financial Performance

The consolidated picture was more challenging with a net loss of ₹986.84 crore on revenue of ₹1,845.32 crore, worsening from ₹779.51 crore loss in FY25. Total borrowings stood at ₹1,035.84 crore as of March 31, 2026, with significant investments in intangible assets under development at ₹61.72 crore.

AGM Details and Corporate Actions

  • Date and Time: September 17, 2026 at 10:30 AM IST via Video Conference
  • Key Agenda Items: Adoption of financial statements, declaration of final dividend of ₹0.20 per share, re-appointment of Managing Director Aditi Panandikar for five years
  • Special Business: Increase in borrowing limits to ₹1,500 crore, approval for creation of charges on assets up to ₹2,000 crore
  • Record Date for Dividend: September 10, 2026; Book Closure: September 11-17, 2026

Business Performance and Operations

Domestic Market Position

Indoco advanced to 20th position in Indian Pharmaceutical Market (IPM) with 10.94 crore prescriptions. The company maintained 40 products in top-5 market positions domestically, with Rexidin M Forte Gel emerging as the No. 1 dentist-prescribed oral care brand.

International Expansion

The company secured significant regulatory approvals including 4 ANDA approvals in US markets, with successful launches of Brivaracetam Oral Solution, Lacosamide Oral Solution, and Rivaroxaban Tablets. The company expanded internationally with product launches in South Africa and new tender wins across Europe, LATAM, and emerging markets.

Manufacturing Excellence

Indoco operates 10 manufacturing facilities producing 348 crore formulation units and 358 MT of API. The facilities maintained regulatory approvals from USFDA, UKMHRA, EDQM, TGA-Australia, WHO GMP, and SAHPRA-South Africa, with USFDA inspection at Patalganga API facility receiving zero observations.

Research and Development

R&D expenditure remained significant at 4.9% of net sales (₹79.5 crore), with 5 new patent applications filed and cumulative portfolio of 123 patent applications globally (54 patents granted). The 100,000 sq. ft. R&D center at Rabale focuses on sterile and complex generics, particularly ophthalmic and injectable products.

Subsidiaries and Corporate Structure

The group includes subsidiaries Xtend Industrial Designers, Warren Remedies, Indoco Remedies Czech, Indoco Remedies UK, and FPP Holding Company (85% ownership). The auditor's report highlighted a qualified opinion for Warren Remedies and going concern considerations for FPP Holding LLC which incurred net loss of ₹2,365.21 lakhs with negative networth.

Key Audit Matters

The auditor identified two key audit matters:

1. Provision for sales returns amounting to ₹248.14 crore based on estimated percentage of sales

2. Capitalization of intangible assets under development at ₹61.72 crore

Corporate Governance and Compliance

The Board comprises 8 Directors with 4 Independent Directors, holding five meetings during FY26. The company maintained full regulatory compliance with no material orders from regulators/courts and zero environmental penalties. CSR expenditure of ₹242.59 lakhs exceeded the obligation of ₹241.63 lakhs.

Forward Outlook

The company continues to invest strategically in OTC/OTX segments and manufacturing upgrades despite current losses. Management remains focused on international expansion, product innovation, and operational efficiency improvements to return to profitability.